Skip to Main Content

Paper Details

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
J Clin Oncol
26
2021
18F-labeled fluorodeoxyglucose, Breast Cancer, C1D15, HER2, PATIENTS, Participants, Patients, Pertuzumab, SULmax, TBCRC026, Trastuzumab, estrogen, estrogen receptor, estrogen receptor-negative and HER2-positive breast cancer, human epidermal growth factor receptor 2, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, patients, pertuzumab, trastuzumab, women
Author NameAffiliation
Lisa A CareyUniversity of North Carolina
Minetta C LiuMayo Clinic
Mothaffar F RimawiBaylor College of Medicine
Anna Maria StornioloMelvin and Bren Simon Cancer Center, Indiana University
Ian E KropDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Antonio C WolffSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Ben Ho ParkSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Ben Ho ParkSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Richard L WahlWashington University
Vered StearnsSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • 1 - 11

Datasets

Release 1.2